Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Inclusion Criteria

• •Histopathologically verified adenocarcinoma of the colon or rectum
• •Metastatic disease
• •Planned treatment with FOLFOX or capecitabine combined with bevacizumab
• •Evaluable disease according to RECIST 1.1
• •Performance status 0-2
• •Expected survival ≥ 3 months
• •Patient acceptance to collection of blood samples for translational research
• •Age ≥ 18 years
• •Contraception during and 6 months after last dose for women of childbearing potential (less than one year amenorrhea and not undergone hysterectomy, bilateral salpingectomy or bilateral oophorectomy) and for male patients with a fertile partner. Hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence is accepted.
• •Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):
• •* WBC ≥ 3.0 x 109/l or neutrophils (ANC) ≥ 1.5 x 10\^9/l
• •* Platelet count ≥ 100 x 10\^9/l
• •* Hemoglobin ≥ 6.0 mmol/l
• •* Serum bilirubin ≤ 2.0 x ULN
• •* Serum transaminase ≤ 2.5 x ULN
• •* Serum creatinine ≤ 1.5 ULN
• •Urine dipstick for protein ≤ 2+, if the dipstick shows protein ≥ 2+, 24 hour urine testing must be performed and show protein contents ≤ 1g.
• •Written and orally informed consent